SECsense Logo

Lixte Biotechnology Holdings, Inc. 8-K Report: Key Insights on Stock and Warrants (Dec 2024)

$LIXT
Form 8-K
Filed on: 2024-12-27
Source
Lixte Biotechnology Holdings, Inc. 8-K Report: Key Insights on Stock and Warrants (Dec 2024)

Based on the provided XML section of the financial report for Lixte Biotechnology Holdings, Inc. (CIK: 0001335105), here are the key insights extracted:

  1. Entity Identification:
  • Name: Lixte Biotechnology Holdings, Inc.
  • CIK: 0001335105
  • Business Address: 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101
  • Contact Number: (631) 830-7092
  1. Report Type and Date:
  • Filing Type: 8-K (current report)
  • Filing Date: December 23, 2024
  1. Stock Information:
  • Common Stock Ticker: LIXT (listed on NASDAQ)
  • Warrant Ticker: LIXTW (listed on NASDAQ)
  1. Financial Reporting Context:
  • The report is presented as of December 23, 2024, with specific references to common stock and warrants to purchase common stock.
  1. Period Specification:
  • The financial data is reported for a single day, December 23, 2024, indicating that this may be a specific event or transaction date rather than a standard quarterly or annual report.
  1. Measurement Units:
  • Financial measures are presented in USD (United States Dollar) and shares, which is typical for stock-related disclosures.
  1. Stock Classifications:
  • The report includes explicit classifications for:
    • Common Stock
    • Warrants to Purchase Common Stock

Insights:

  • The filing indicates that Lixte Biotechnology is actively reporting on its equity instruments, which may be relevant for investors or analysts monitoring its financing activities, particularly given the presence of warrants, which could indicate potential future dilution or capital raising.
  • The single-day reporting period suggests a recent event or change that may have significant implications for shareholders, such as a new issuance of stock, a merger, or other corporate actions.
  • The presence of warrants may suggest investor interest or capital-raising strategies that could affect the company's future financial position.

Overall, this report is crucial for stakeholders interested in Lixte Biotechnology's current financial obligations and equity structure.